Humanized CD19-Directed CARs for Selective Cancer Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy, affect both healthy and diseased cells, leading to potential survival issues for patients, while immunotherapies targeting specific cancer markers are limited in efficacy and specificity.
Innovation Solution
Engineering immune cells, particularly NK and T cells, to express CD19-directed chimeric antigen receptors (CARs) with specific binding and signaling domains, including anti-CD19 scFv, CD8 alpha hinge, CD8 alpha transmembrane, OX40, and CD3 zeta domains, to target and destroy cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If chemotherapy is used to treat cancer, then cancer cells are killed, but healthy cells are also damaged
Solution Approach 1:
The treatment approach is segmented into highly specific targeting components. The chimeric antigen receptor is divided into distinct functional domains: an extracellular antigen-binding domain that specifically recognizes CD19 on B-cell lineage cancer cells, a transmembrane domain, and intracellular signaling domains (including CD3ζ and costimulatory domains). This segmentation enables the immune cell to selectively identify and destroy only cancer cells expressing CD19, sparing healthy cells that do not express this antigen.
Solution Approach 2:
The chimeric antigen receptor acts as an intermediary molecule that bridges the immune cell and the cancer cell. The extracellular domain of the CAR specifically binds to CD19 on the cancer cell surface, while the intracellular domain transmits signaling to the immune cell to activate cytotoxicity. This intermediary structure enables precise targeting without the non-specific damage caused by traditional chemotherapy.
2Measurement precision
If immunotherapies target specific cancer markers, then specificity is improved, but efficacy is limited
Solution Approach 1:
The chimeric antigen receptor merges multiple functional elements into a single engineered protein: the antigen-binding domain (providing specificity for CD19), the transmembrane anchoring domain, and multiple intracellular signaling domains including CD3ζ for activation and costimulatory domains (such as 4-1BB or CD28) for sustained signaling and immune cell survival. This merging of functions within one receptor structure overcomes the limited efficacy of previous immunotherapies while maintaining high specificity.
Solution Approach 2:
The CAR is a composite molecular structure combining elements from different sources and functions. The extracellular domain may be derived from antibody variable regions for antigen binding, while the intracellular signaling domains are derived from various immune receptors. This composite design creates a molecule that simultaneously provides specific targeting, strong activation signaling, and sustained immune cell function, thereby improving treatment efficacy while maintaining specificity.
Data Source
AI summary
Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.